Keros Therapeutics Appoints Keith Regnante as Chief Financial Officer
February 25, 2020
Share
Keros Therapeutics, Inc. announced the appointment of Keith Regnante as Chief Financial Officer (CFO). Mr. Regnante brings more than 20 years of financial experience in progressively senior roles in the biotechnology sector, where he has helped build and lead high performing teams to define and execute strategy while driving sustainable growth. As CFO, Mr. Regnante will lead financial and information technology operations, together with overseeing investor relations and fundraising efforts. Mr. Regnante joins Keros from Wave Life Sciences, where he served as Chief Financial Officer during a time of considerable organizational growth, clinical pipeline advancements and multiple capital raises. Prior to joining Wave, Mr. Regnante was a Vice President of Finance at Shire where he oversaw finance for Research & Development (R & D). Prior to Shire, Mr. Regnante held a number of positions of increasing responsibility at Biogen, including leading the finance teams for Corporate Finance, R & D and Business Development. Earlier in his career, Mr. Regnante was a Consultant with The Boston Consulting Group.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
KEROS THERAPEUTICS, INC. 
